Siu evaluated the activity of erlotinib on a patient-derived chordoma xenograft; he showed a strong druggable activation of EGFR: exposure of tumor cells to erlotinib resulted in a dimensional anti-tumor response concurrent to a reduction of phosphorylation of Tyr845 residue, thus supporting a favorable clinical usage (18). The gene discussed is EGFR; the disease is neoplasm.